Cardiovagal autonomic dysfunction in relation to HIV-associated lipodystrophy

被引:7
|
作者
Chow, DC
Wood, R
Grandinetti, A
Shikuma, C
Schatz, I
Low, P
机构
[1] Univ Hawaii Manoa, Dept Internal Med, Hawaii AIDS Clin Res Program, Honolulu, HI 96822 USA
[2] Univ Hawaii Manoa, Dept Pediat, Hawaii AIDS Clin Res Program, Honolulu, HI 96822 USA
[3] Louisiana State Univ, Dept Kinesiol, Baton Rouge, LA 70803 USA
[4] Univ Hawaii Manoa, Dept Publ Hlth & Epidemiol, Honolulu, HI 96822 USA
[5] Univ Hawaii Manoa, Dept Internal Med, Honolulu, HI 96822 USA
[6] Mayo Clin, Dept Neurol, Rochester, MN USA
来源
HIV CLINICAL TRIALS | 2006年 / 7卷 / 01期
关键词
autonomic function; HIV; lipodystrophy;
D O I
10.1310/B6PT-56HG-K3DN-84KK
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Human immunodeficiency virus (HIV)-associated lipodystrophy (LD) may be mediated by changes in the autonomic nervous system. We examined the autonomic function among HIV-infected patients with LD compared to HIV-infected patients without LD (non-LD) and HIV-negative controls (controls). Method: This cross-sectional study examined cardiovagal autonomic function among the three groups. LD was defined in HIV-infected patients as increased visceral adipose accumulation and peripheral lipoatrophy. Cardiovagal autonomic testing was assessed by measuring heart rate variability during rest, paced breathing, and upright tilt and was analyzed in time and frequency domains. Results: Cardiovagal testing was performed on 58 participants: 26 controls, 20 non-LD, and 12 LD. After adjustment for visceral fat, time domain analysis showed decreased heart rate variability in patients with LD compared to the other groups (p < .05). The frequency domain analysis showed decreased high-frequency power and increased low- to high-frequency power ratio in the LD group compared to both groups during rest and to non-LD during tilt (p < .05). Conclusion: Patients with LD have altered cardiovagal modulation. Patients with LD had lower heart rate variability and higher sympathetic modulation compared to non-LD and controls. These alterations may be prognostic of increased cardiovascular disease morbidity and mortality.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 50 条
  • [1] The HIV-associated lipodystrophy syndrome
    Mauss, S
    Schmutz, G
    MEDIZINISCHE KLINIK, 2001, 96 (07) : 391 - 401
  • [2] HIV-ASSOCIATED LIPODYSTROPHY AND EXERCISE
    Mutimura, E.
    Stewart, A.
    Crowther, N. J.
    SOUTH AFRICAN JOURNAL OF PHYSIOTHERAPY, 2006, 62 (02) : 2 - 4
  • [3] HIV-associated lipodystrophy syndrome
    Qaqish, RB
    Fisher, E
    Rublein, J
    Wohl, DA
    PHARMACOTHERAPY, 2000, 20 (01): : 13 - 22
  • [4] HIV-associated lipodystrophy syndrome
    Milinkovic, Ana
    COLLEGIUM ANTROPOLOGICUM, 2006, 30 : 59 - 62
  • [5] HIV-associated lipodystrophy syndrome
    Mauss, S
    AIDS, 2000, 14 : S197 - S207
  • [6] Experience in the treatment of HIV-associated lipodystrophy
    Nelson, L.
    Stewart, K. J.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2008, 61 (04): : 366 - 371
  • [7] Spotlight on Tesamorelin in HIV-Associated Lipodystrophy
    Sohita Dhillon
    BioDrugs, 2011, 25 : 405 - 408
  • [8] Clinical management of HIV-associated lipodystrophy
    Pirmohamed, Munir
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (04) : 309 - 314
  • [9] Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1363): : 34 - 35
  • [10] HIV-associated asymmetric lipodystrophy syndrome
    Quiros-Roldan, E
    Moretti, F
    Torti, C
    Casari, S
    Prestini, K
    Carosi, G
    REVISTA CLINICA ESPANOLA, 2004, 204 (03): : 177 - 177